Alk-Abello AS (AKBLF) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Upgraded Outlook
Q2 Revenue Growth: Up 21% organically, with double-digit growth in all AIT vaccine categories. Tablet Sales Growth: 32% globally, 35% in Europe. European Sales Growth: Up 25%, driven by tablets and SC...